1. Home
  2. AQMS vs NEUP Comparison

AQMS vs NEUP Comparison

Compare AQMS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aqua Metals Inc.

AQMS

Aqua Metals Inc.

N/A

Current Price

$5.06

Market Cap

20.9M

Sector

Industrials

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$4.39

Market Cap

23.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AQMS
NEUP
Founded
2014
1996
Country
United States
United States
Employees
N/A
8
Industry
Metal Fabrications
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
23.0M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
AQMS
NEUP
Price
$5.06
$4.39
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$12.00
$21.00
AVG Volume (30 Days)
82.2K
25.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,100,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$550.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$3.65
52 Week High
$39.37
$21.31

Technical Indicators

Market Signals
Indicator
AQMS
NEUP
Relative Strength Index (RSI) 43.75 57.93
Support Level $4.62 $3.95
Resistance Level $8.37 $4.43
Average True Range (ATR) 0.34 0.13
MACD 0.05 0.04
Stochastic Oscillator 72.29 71.00

Price Performance

Historical Comparison
AQMS
NEUP

About AQMS Aqua Metals Inc.

Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: